<DOC>
	<DOCNO>NCT02037373</DOCNO>
	<brief_summary>Post-Marketing Requirement study evaluate safety octaplas™ versus plasma patient undergo orthotopic liver transplantation ( OLT ) . The primary objective ass incidence hyperfibrinolysis patient undergo ( OLT ) receive octaplas™ versus regular plasma ( e.g. , fresh frozen plasma FDA AABB approve plasma product ) .</brief_summary>
	<brief_title>Post-Marketing Requirement Evaluate Safety Octaplas™ Versus Plasma Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis Hyperfibrinolysis .</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<criteria>Male female age ≥18 year Patient schedule undego orthotopic liver transplantation ( OLT ) Patient natural MAYO EndStage Liver Disease ( MELD ) score 1540 Patient willing give voluntary write informed consent study related procedure perform part standard medical care , understand consent may withdraw subject time without prejudice future medical care Patient history severe hypersensitivity reaction plasmaderived product excipient investigational product Patient know IgA deficient document antibody IgA Patient plan recipient living donor OLT Patient severe deficiency Protein S Patient currently participate interventional clinical study participate one within 30 day date OLT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>intra post-op coagulopathy patient undergoing OLT</keyword>
</DOC>